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The study aimed to identify genetic lesions associated with secondary acute myeloid leukemia (sAML) in
comparison with AML arising de novo (dnAML) and assess their impact on patients’ overall survival (OS).
High-resolution genotyping and loss of heterozygosity mapping was performed on DNA samples from 86
sAML and 117 dnAML patients, using Affymetrix Genome-Wide Human SNP 6.0 arrays. Genes TP53,
RUNX1, CBL, IDH1/2, NRAS, NPM1, and FLT3 were analyzed for mutations in all patients. We identified 36
recurrent cytogenetic aberrations (more than five events). Mutations in TP53, 9pUPD, and del7q (targeting
CUX1 locus) were significantly associated with sAML, while NPM1 and FLT3 mutations associated
with dnAML. Patients with sAML carrying TP53 mutations demonstrated lower 1-year OS rate than those
with wild-type TP53 (14.3% ± 9.4% vs. 35.4% ± 7.2%; P 5 0.002), while complex karyotype, del7q (CUX1) and
del7p (IKZF1) showed no significant effect on OS. Multivariate analysis confirmed that mutant TP53 was
the only independent adverse prognostic factor for OS in sAML (hazard ratio 2.67; 95% CI: 1.33–5.37; P 5
0.006). Patients with dnAML and complex karyotype carried sAML-associated defects (TP53 defects in
54.5%, deletions targeting FOXP1 and ETV6 loci in 45.4% of the cases). We identified several co-occurring
lesions associated with either sAML or dnAML diagnosis. Our data suggest that distinct genetic lesions
drive leukemogenesis in sAML. High karyotype complexity of sAML patients does not influence OS. So-
matic mutations in TP53 are the only independent adverse prognostic factor in sAML. Patients with dnAML
and complex karyotype show genetic features associated with sAML and myeloproliferative neoplasms.
Am. J. Hematol. 87:1010–1016, 2012. VC 2012 Wiley Periodicals, Inc.
Introduction
The continuous production of terminally differentiated
blood cells in the hematopoietic system is a tightly regu-
lated process involving self-renewal, proliferation, and dif-
ferentiation of stem and progenitor cells. Disruption of this
process by acquired genetic lesions may cause the domi-
nance of stem cell clones with variable output of myeloid
cells. As a consequence, the production of terminally
differentiated cells may be excessive resulting in myeloproli-
ferative neoplasms (MPN) or deficient accompanied with
dysplasia, with or without the presence of blasts, resulting
in myelodysplastic syndromes (MDS).
The classic BCR-ABL-negative MPNs include three dis-
ease entities—polycythemia vera (PV), essential thrombo-
cythemia (ET), and primary myelofibrosis (PMF) [1]. In
95% of PV and approximately half of ET and PMF cases
the initiation of the clinical phenotype is hallmarked by so-
matic mutations in the JAK2 gene [2–5], often amplified to
homozygosity by uniparental disomy (UPD) of chromosome
9p [6]. MDS are a heterogeneous group of disorders and a
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number of genetic lesions have been implicated in their
pathogenesis, including del5q [7], as well as mutations in
the RNA splicing pathway [8], TET2 [9], EZH2 [10], and
other genes. MPN and MDS are chronic disorders with an
elevated risk of disease progression to secondary acute
myeloid leukemia (sAML). The rate of leukemic transforma-
tion in BCR-ABL-negative MPN patients is 7% [11], while
MDS patients transform in 30% of the cases [12]. Disease
progression to sAML is characterized by the presence of
>20% of blasts in the bone marrow and sequential acquisi-
tion of genetic aberrations [13,14]. Although several studies
on limited patient cohorts showed association of gene
mutations and cytogenetic aberrations with leukemic trans-
formation of MPN and MDS, the leukemogenesis process
remains poorly understood. Mutations in FLT3, NRAS [15],
NPM1 [16], RUNX1 [17], DNMT3A [18], IDH1, IDH2 [19],
TET2 [20,21], and TP53 [22] have been implicated in leuke-
mic transformation, as well as several chromosomal aberra-
tions, such as deletions of IKZF1 [23], JARID2, AEBP2
[24], and amplifications of MDM4 [22].
Studies of clonal hierarchy showed that sAML can arise
on the background of the chronic phase founder clone or
alternatively as an independent event, resembling dnAML
[25–27]. Unlike dnAML patients who often achieve complete
remission after treatment, patients who transform to sAML
have very poor prognosis and die within a few months follow-
ing AML diagnosis [28], suggesting that leukemogenesis
must differ substantially between sAML and dnAML.
Since the genetic basis of sAML is mainly unknown, the
aim of our study was to delineate genetic profiles of sAML
patients using high-resolution genome-wide single-nucleo-
tide polymorphism (SNP) arrays, as well as direct sequenc-
ing of genes known to be involved in AML pathogenesis.
Furthermore, we aimed to compare the frequency of recur-
rent genetic lesions in sAML and dnAML, and analyze their
prognostic significance in order to define which genetic
aberrations account for the poor prognosis of sAML
patients. We used a bioinformatic approach to study co-
occurrence of genetic aberrations and their association with
patient diagnosis, in order to identify new genes involved in
leukemogenesis and define potential new markers that
would allow better genetic stratification of AML patients.
Methods
Patient samples. A total of 203 patients were included in this study,
117 diagnosed with dnAML and 86 with sAML. Patients diagnosed with
therapy-related AML were not included in the study. Patients were diag-
nosed as sAML according to the 2008 WHO classification, and all sam-
ples were collected at the time of sAML diagnosis. Time to leukemic
transformation was measured from the time of MPN/MDS diagnosis to
the date of sAML diagnosis. Clinical data were available for 184
patients (110 dnAML and 74 sAML). Classical cytogenetic analysis was
performed according to routine cytogenetic procedures, using GTG-
banding technique. Peripheral blood samples from patients were col-
lected from institutions in Italy, Austria, Czech Republic, and Serbia, fol-
lowing the local ethical regulations. Genomic DNA was isolated from
granulocytes, bone marrow, or whole blood samples, following standard
protocols.
Microarray analysis. All patients’ DNA samples were processed and
hybridized to Genome-Wide Human SNP 6.0 arrays (Affymetrix, Santa
Clara, CA) according to the manufacturer’s instructions. Raw data were
analyzed using Genotyping Console Version 3.0.1 software (Affymetrix,
Santa Clara, CA) for quality, identification of copy number alterations,
and losses of heterozygosity. Detected chromosomal aberrations
(gains, deletions, and UPDs) were annotated. The criteria for annotat-
ing UPD regions were terminal location on the chromosome and size
of >1 Mb. UPDs found in patients with numerous interstitial runs of
homozygosity (>10 Mb) were excluded from further analysis, as they
infer parental consanguinity [29]. All aberrations mapping to known
copy number variation loci according to the Database of Genomic Var-
iants (DGV Version 5, human reference genome assembly hg18) were
not annotated.
Mutational analysis. Exon sequencing of all coding exons of
RUNX1, TP53, as well as exon 1 of NRAS, exons 8 and 9 of CBL,
exons 4 of IDH1 and IDH2 was performed using BigDye Terminator
Version 3.1 cycle-sequencing kit and the 3130xl Genetic Analyzer
(Applied Biosystems, Foster City, CA). Sequencher Version 4.9 soft-
ware (Gene Codes Corporation, Ann Arbor, MI) was used for sequence
analysis. Screening of FLT3 internal tandem duplications, FLT3 muta-
tions at position D835 and insertions in exon 12 of NPM1 were per-
formed as previously described [30,31]. All primer sequences are listed
in Supporting Information Table I.
Statistical analysis. Patient characteristics, frequencies of muta-
tions, and chromosomal aberrations were compared using the Fisher’s
exact test for categorical data and Mann-Whitney test for continuous
data. OS was measured from the date of AML diagnosis to time of
death from any cause. Patients were censored at the time of the last
follow-up. In the sAML patient cohort 52 patients died during the follow-
up, while 22 patients were censored. Survival curves were constructed
using the Kaplan-Meier method. The comparison of OS curves was
performed using the log-rank test and multivariate analysis of OS using
the Cox regression model. All calculated P values are two-tailed. SPSS
20.0 (SPSS, Chicago, IL) statistical software package was used for sta-
tistical analyses. The negative interaction information analysis was per-
formed as described in the Supporting Information methods.
Results
Patient characteristics
The study included a total of 203 patient samples, diag-
nosed with sAML (N 5 86) or de novo AML (N 5 117). The
sAML patient cohort consisted of 48 patients with a previous
diagnosis of MPN, 36 with MDS, and 2 with MPN/MDS over-
lap. The median duration of chronic phase before transforma-
tion was 5 years (range 0.2–22.8). Clinical characteristics of
the patient cohort are summarized in Supporting Information
Table II. Patients with sAML were treated according to differ-
ent therapeutic protocols (Supporting Information Table III),
however, this did not influence the outcome since most sAML
patients did not respond to therapy. Nine sAML patients
received allogeneic hematopoietic stem cell transplantation.
Frequencies of mutations in genes associated with
AML differ between sAML and dnAML
To investigate whether the frequency of mutations in
genes commonly affected in dnAML is the same in sAML we
screened for mutations in FLT3, NPM1, TP53, CBL, IDH1,
IDH2, RUNX1, and NRAS (Fig. 1A) in both patient groups.
Within the sAML patient cohort we did not observe any sig-
nificant difference in frequency of mutations with respect to
the previous diagnosis (Supporting Information Fig. 2). At
least one gene mutation was found in 56.41% of dnAML and
52.38% of sAML patients. In dnAML patients the most fre-
quent were NPM1 mutations, present in 24.79% (29 of 17)
of cases, followed by FLT3 mutations found in 23.93% (28 of
117) of patients. The frequency of these mutations was sig-
nificantly lower in sAML patients, where NPM1 was mutated
in 4.94% and FLT3 in 7.23% of cases (P 5 0.002 and P 5
0.016, respectively). In contrast, TP53 mutations were found
in 16.67% of sAML and only 4.27% of dnAML cases (P 5
0.046). The frequencies of mutations in RUNX1, IDH1,
IDH2, CBL, and NRAS were not significantly different in the
two patient groups (Fig. 1A). TP53 and RUNX1 mutations
mainly affected the DNA-binding domains of these proteins
(Supporting Information Fig. 1). The list of all mutations in
analyzed genes and their PolyPhen-2 prediction scores of
functional effects are listed in Supporting Information Table
IV. Furthermore, we observed that certain mutations co-
occur, while others show mutual exclusivity (Fig. 1B–E). Co-
occurrence of NPM1 and FLT3 mutations was observed in
dnAML only, while RUNX1 and FLT3 mutations co-occurred
in 4 dnAML and 2 sAML patients (Fig. 1B,C). In both patient
groups, IDH1 and IDH2 mutations were mutually exclusive.
Mutations in TP53 were found to be mutually exclusive with
IDH1/2 in sAML (Fig. 1E).
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Microarray-based karyotyping of sAML and dnAML
To get a deeper insight into the genetic complexity of
sAML and dnAML, we performed high-resolution genome-
wide analysis of DNA copy number abnormalities and losses
of heterozygosity on 200 samples (114 dnAML and 86
sAML) using Affymetrix Genome-Wide SNP 6.0 arrays.
Comparing with only 11.4% of dnAML cases, 44.2% of
sAML patients presented with a complex karyotype (P <
0.0001), defined as more than or equal to three unrelated
chromosomal aberrations not included in the WHO 2008
classification criteria [13]. In 17.4% (15 of 86) of the sAML
cases we could not detect any chromosomal aberration,
which was significantly lower comparing with 37.7% (43 of
114) of such dnAML patients (P 5 0.0017). In the remaining
samples we detected a total of 669 chromosomal aberra-
tions, mainly deletions (59%, 395 of 669), but also gains
(27.95%, 187 of 669) and UPDs (13%, 87 of 669) (Fig. 2).
We found 36 recurrent chromosomal aberrations, present in
more than five patients in our cohort (Table I). High number
of deletions allowed the fine mapping of common deleted
regions (CDR) to <1 Mb on specific chromosomal arms,
pointing out the possible target genes, such as CUX1,
IKZF1, TET2, JARID2, SUZ12, RUNX1, TET1, and NF1.
We compared the frequency of recurrent chromosomal
aberrations in the two patient groups and found that 18 out
of 36 recurrent cytogenetic aberrations show a bias toward
sAML. However, after applying Bonferroni correction for mul-
tiple testing, only four chromosomal aberrations significantly
associated with sAML (Table I). The strongest association
was observed for 9pUPD, as a consequence of high preva-
lence of this aberration in chronic phase of MPN. The sec-
ond strongest association was observed between sAML and
del7q22.1 mapping to tumor suppressor CUX1 locus. Inter-
estingly, gains of chromosome 1q32.1, targeting the MDM4
locus, were found exclusively in sAML patients (N 5 6).
We also compared the frequency of recurrent chromo-
somal aberrations in sAML patients who developed AML
following MPN or MDS chronic phase, and found that
besides 9pUPD which showed association with previous
MPN diagnosis, all other aberrations occurred in similar fre-
quencies in both post-MPN and post-MDS AML (Sup-
porting Information Table V).
All patients with 13qUPD (N 5 7) and 17pUPD (N 5 4)
were carrying homozygous mutations in FLT3 and TP53,
respectively. Both TP53 alleles were affected in 13 out of
19 patients with TP53 mutations (Supporting Information
Table VI). CBL mutations were amplified by 11qUPD in four
cases, however, three sAML patients with 11qUPD did not
carry mutations in CBL.
Association of recurrent genetic lesions
In order to analyze the association of recurrent genetic
lesions, we performed Fisher’s exact test on all pairs of an-
Figure 1. Gene mutation profiles in secondary (sAML) and de novo acute myeloid leukemia (dnAML). (A) Comparison of mutational frequencies in genes affected in
myeloid malignancies shows significant bias of FLT3 and NPM1 mutations toward dnAML and TP53 toward sAML. All P values have been corrected for multiple testing
using the Bonferroni correction. The co-occurrence of mutations in dnAML (B) and sAML (C) is shown with Circos diagrams [32]. The length of the arc corresponds to
the frequency of mutations in the individual gene, while the width of the ribbons connecting two arcs corresponds to the number of patients carrying both mutations.
Certain mutations show mutual exclusivity in both dnAML (D) and sAML (E). Each vertical line represents one patient with at least one mutation.
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alyzed gene mutations and recurrent cytogenetic aberra-
tions (more than five events), provided they are located on
different chromosomes. Supporting Information Table VII
lists all significant aberration pairs (N 5 16). Del5q was
found to be associated with TP53 mutations (P 5 0.0004),
del12p targeting ETV6 locus (P 5 0.0022), del17p (P 5
0.0159), and del7q (P 5 0.0251). We also found associa-
tion of del18q with gain of 20q (P 5 0.0033) and del4q tar-
geting TET2 locus with del20q (P 5 0.0153).
The negative interaction information analysis was per-
formed to detect the pairs of aberrations that have different
patterns of association (co-occurrence or mutual exclusiv-
ity) depending on the disease subtype. The top 100 hits
obtained from this analysis are listed in Supporting Informa-
tion Table VIII. We observed that del5q frequently occurs
together with 9pUPD and TP53 mutations in sAML patients,
and that TP53 mutations and del10q targeting TET1 gene
locus are present at the same time in four sAML patients,
while these aberrations never co-occur in dnAML.
Prognostic significance of recurrent genetic lesions
In order to define which genetic feature had the most
adverse effect on the survival of patients with sAML, we an-
alyzed the influence of mutations in TP53, del7q (CUX1),
del7p (IKZF1), and presence of complex karyotype. These
features were chosen because they were found to associate
with sAML and are rare in both dnAML and chronic phase of
MPN and MDS [31]. We focused our analysis on overall sur-
vival since most of the sAML patients did not respond to
therapy or died early following sAML diagnosis. Patients with
sAML carrying TP53 mutations showed a significantly
shorter median OS (1.8 months, 95% CI, 0.8–2.8), com-
pared with patients with wild-type TP53 (5.6 months, 95%
CI, 1.5–9.7; P 5 0.002) (Fig. 3A). Karyotype complexity did
not show a significant impact on OS of sAML patients. The
Figure 2. Whole-genome view of all chromosomal aberrations and gene mutations in 86 sAML and 117 dnAML patients. Each line represents the whole genome of one
patient in which at least one genetic aberration was detected with Affymetrix Genome-Wide Human SNP 6.0 arrays. The size and physical position of each chromosomal
aberration is represented with a colored bar. Deletions are represented in red, gains in green, and uniparental disomies in blue. Mutations in analyzed genes are shown
as filled boxes. UPN, unique patient number.
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Figure 3. Impact of recurrent genetic lesions and karyotype complexity on overall survival (OS) of patients with secondary acute myeloid leukemia (sAML) represented
by Kaplan-Meier curves. (A) OS in sAML patients with mutated (N 5 14) or wild-type TP53 (N 5 59). (B) OS in sAML patients with complex (N 5 31) or noncomplex (N
5 43) karyotype. (C) OS of sAML patients according to presence (N 5 17) or absence (N 5 57) of del7q targeting CUX1 locus. (D) OS of sAML patients according to
presence (N 5 9) or absence (N 5 65) of del7p targeting IKZF1 locus.
TABLE I. Association of Recurrent (More Than Five Events) Chromosomal Aberrations with Patient Diagnosis
Chromosomal
aberration
Start
position End position
Chromosomal
band
% of sAML
patients
% of dnAML
patients
Total no.
events
Target
gene locus P
P value after
Bonferroni
correction
9p UPD 1 9,000,000 9p24.3 17.4 0 15 <0.001 <0.01
7q LOSS 101,350,000 102,000,000 7q22.1 20.9 4.4 23 CUX1 <0.001 0.018
7q LOSS 65,180,000 65,830,000 7q11.21 13.9 1.75 14 0.001 0.043
7q LOSS 148,400,000 150,400,000 7q36.1 22.1 6.1 26 0.001 0.043
20q LOSS 35,000,000 35,100,000 20q11.23 8.1 0 7 0.002 0.086
4q LOSS 106,000,000 10,664,0000 4q24 10.5 0.9 10 TET2 0.005 0.191
20q LOSS 36,000,000 36,170,000 20q11.23 9.3 0.9 9 0.005 0.198
1q GAIN 201,000,000 204,496,000 1q32.1 7 0 6 0.006 0.205
9q GAIN 78,900,000 79,650,000 9q21 7 0 6 0.006 0.205
20q LOSS 33,500,000 34,000,000 20q11 7 0 6 0.006 0.205
7p LOSS 11,000,000 18,000,000 7p21 11.6 2.6 13 0.017 0.63
7p LOSS 50,080,000 50,600,000 7p12.2 13.9 4.4 17 IKZF1 0.021 0.752
7p LOSS 38,200,000 38,390,000 7p14.1 12.8 3.5 15 0.027 0.968
5q LOSS 130,900,000 139,400,000 5q31 18.6 7.9 25 0.030 1
5q LOSS 89,489,000 95,350,000 5q14->q15 16.3 6.1 21 0.034 1
Monosomy 7 8.1 1.7 9 0.040 1
9p GAIN 1 38,761,000 9p24 7 0.9 7 0.044 1
11q UPD 118,500,000 134,452,384 11q23.3->qter 7 0.9 7 0.044 1
6p LOSS 5,150,000 5,460,000 6p25.1 5.8 0.9 6 0.086 1
6p LOSS 14,130,000 15,800,000 6p23 5.8 0.9 6 JARID2 0.086 1
6p LOSS 19,955,000 20,820,000 6p22.3 5.8 0.9 6 0.086 1
18q LOSS 75,100,000 75,950,000 18q23 5.8 0.9 6 0.086 1
12p LOSS 11,800,000 12,900,000 12p13 10.5 4.4 14 ETV6 0.159 1
3p LOSS 71,600,000 73,000,000 3p13 1.2 5.3 7 FOXP1 0.242 1
Trisomy 8 12.8 8 18 0.341 1
20q GAIN 29,300,000 30,520,000 20q11.21 4.6 1.7 6 0.405 1
17q LOSS 26,000,000 26,600,000 17q11.2 9.3 6.1 15 NF1 0.427 1
21q GAIN 45,700,000 46,400,000 21q22.3 5.8 3.5 9 0.503 1
21q GAIN 36,300,000 40,250,000 21q22 5.8 4.4 10 0.748 1
17q LOSS 27,200,000 27,400,000 17q11.2 8.1 7 15 SUZ12 0.792 1
9q LOSS 92,300,000 93,850,000 9q22 2.3 3.5 6 1 1
13q UPD 106,100,000 114,142,980 13q33->qter 3.5 4.4 8 1 1
21q GAIN 13,280,000 27,000,000 21q11->q21 4.6 4.4 9 1 1
12q LOSS 92,900,000 93,400,000 12q22 3.5 2.6 6 1 1
17p LOSS 4,850,000 5,170,000 17p13.2 4.6 4.4 9 1 1
17p LOSS 7,080,000 8,080,000 17p13.1 4.6 5.3 10 1 1
UPD, uniparental disomy; sAML, secondary acute myeloid leukemia; dnAML, de novo acute myeloid leukemia.
median survival of sAML patients with complex karyotype
was 4 months (95% CI, 2.5–5.5), while the OS of patients
with noncomplex karyotype was 8 months (95% CI,
3.0–13.0) (Fig. 3B). The effect of del7q (CUX1) and del7p
(IKZF1) on OS of sAML patients was not significant
(Fig. 3C,D). We included age, complex karyotype, mutations
in TP53, del7p, and del7q in the model and performed multi-
variate analysis of OS of sAML patients. The multivariate
analysis confirmed that mutated TP53 was the only inde-
pendent adverse prognostic factor for OS (hazard ratio 2.67;
95%CI, 1.33–5.37; P 5 0.006) in sAML (Table II).
De novo AML patients with complex karyotype exhibit
genetic features of secondary AML
There were 11 dnAML patients with complex karyotype
in our patient cohort with available clinical data. The me-
dian OS of these patients was 3 months (95% CI, 2.0–4.0),
and all patients died during the follow-up. To gain better
understanding of poor OS of patients with complex karyo-
type within the dnAML group we looked at genetic profiles
of each of these patients (Table III) and found that TP53
was affected in 54.5% (N 5 6 of 11) of these patients.
TP53 mutations were present in three patients, and addi-
tional three patients carried a deletion of TP53 locus on
chromosome 17p. TP53 mutations were only present in this
subtype of dnAML. We also found del7p (IKZF1) and del7q
(CUX1) in four and three patients, respectively. In addition,
these patients carried deletions mapping to the transcrip-
tion factors FOXP1 (45.4%, N 5 5 of 11) and ETV6
(45.4%, N 5 5 of 11) (Table III). Taken together we
observed a number of genetic features present in dnAML
with complex karyotype typical for either MPN or sAML.
Discussion
The objective of this study was to examine to what
extent the genetic basis of leukemogenesis in post-MPN
and post-MDS AML differs from dnAML, by systematic
analysis of genetic profiles of sAML and dnAML patients.
We grouped the patients who developed sAML after MPN
or MDS chronic phase, since we did not observe any
genetic difference between the two groups in the leukemic
stage. The comparison of mutational frequency in genes
known to be affected in myeloid malignancies showed that
TP53 mutations significantly associated with sAML,
whereas NPM1 and FLT3 were prominently involved in
dnAML. IDH1/2, NRAS, RUNX1, and CBL mutations seem
to be universally contributing to dnAML and sAML leuke-
mogenesis. The mutual exclusivity of certain mutations
such as IDH1/2 with CBL, TP53 and with NRAS confirms
that distinct leukemogenic pathways are involved in
sAML [33].
We extended the genetic marker analysis by karyotyp-
ing patients with high-resolution SNP arrays. The high
number of chromosomal aberrations observed enabled us
to fine map CDRs to several putative tumor suppressor
gene loci (Table I). Compared with dnAML, we observed
higher karyotype complexity in sAML and identified a num-
ber of cytogenetic lesions differentially distributed in both
AML groups. Previous attempts to identify karyotype dif-
ferences between sAML and dnAML were limited with the
use of classical cytogenetic methods, although the associ-
ation of del7q with sAML was previously reported [34].
Association of del7q was recently confirmed by SNP array
karyotyping and the 7q CDR was mapped to the CUX1
locus [31]. Cux1 deficiency negatively affects the expres-
sion of ATM/p53 pathway members [35]. CUX1 deletions
in sAML must have a weaker effect on DNA damage
response pathways compared with mutated TP53 as we
did not observe influence of CUX1 deletions on OS of
patients, whereas mutated TP53 negatively impacts OS.
Our study convincingly showed for the first time that
mutated TP53 in sAML is a strong independent prognostic
factor of poor survival. Previous reports showed worse
survival of TP53 mutated dnAML patients with complex
karyotype [36,37]. The importance of p53 in the leukemo-
genesis of sAML is further supported by our finding that
gains of 1q32.1 harboring the MDM4 (known inhibitor of
p53) were found exclusively in secondary AML. They often
co-occurred with del7q (CUX1) (N 5 4 cases), suggesting
that DNA damage response pathway defects play a crucial
role in sAML pathogenesis.
A recent report of complex clonal architecture in sAML,
showing various rare mutations in each patient [14] high-
lights the need for identification of robust genetic markers
with relatively high frequency. Since monoallelic TP53 muta-
tions are detectable in chronic phase MPN [22] and MDS
[38] (3.5% and 7.5% of the cases, respectively), screening
for TP53 mutations in chronic myeloid malignancies could
be a useful marker predicting leukemic transformation.
The analysis of pair-wise association of genetic aberra-
tions identified several new collaborating defects, such as
del5q and del12p (ETV6), which require further functional
validation. We confirmed previous reports that TP53 muta-
tions are often found together with 5q deletions [39]. It is
unclear at this point to what extent the poor prognosis asso-
ciated with mutated TP53 is influenced by 5q deletions.
The high rate of karyotype complexity and its nonsignifi-
cant effect on OS in sAML suggests that many chromo-
TABLE II. Multivariate Analysis of Overall Survival Duration of Patients with
Secondary Acute Myeloid Leukemia
Variables Hazard ratio 95% CI P
TP53 mutation 2.67 1.33–5.37 0.006
Complex karyotype 1.31 0.69–2.49 0.411
Del7q (CUX1) 0.76 0.33–1.75 0.527
Del7p (IKZF1) 1.27 0.43–3.78 0.659
Age 2.18 0.97–4.90 0.059
TABLE III. Clinical and Genetic Characteristics of De Novo Acute Myeloid Leukemia Patients with Complex Karyotype
UPN Sex Age FAB
Overall
survival
(months)
Complex
karyotype NPM1 FLT3 IDH1/2 RUNX1 NRAS CBL TP53 del17p
del7q
(CUX1)
del3p
(FOXP1)
del7p
(IKZF1)
del12p
(ETV6)
4 F 30 M0 0.5 Yes Wt Wt Wt Wt Wt Wt Wt – – – Yes –
11 M 41 M5 3 Yes Wt Wt Wt Wt Wt Wt Wt – – – – –
42 F 30 M2 5 Yes Wt Wt Wt Wt G13D Wt Wt – – – – –
44 F 61 M2 3 Yes Wt Wt Wt Wt Wt Wt Wt Yes – Yes Yes Yes
51 F 63 M6 0.5 Yes Wt Wt Wt S418Pfs Wt Wt Y220C Yes Yes – – –
67 M 55 M2 3 Yes Wt Wt Wt Wt Wt Wt Wt Yes – – – –
68 F 66 M2 1 Yes Wt Wt Wt Wt G12C Wt S215G/R337C – Yes – yes Yes
72 F 82 M4 2 Yes Wt Wt Wt Wt G12D Wt Wt – Yes Yes yes Yes
86 M 50 M1 3.4 Yes Wt Wt Wt Wt Wt Wt Wt Yes – Yes – Yes
104 M 60 M4 10.6 Yes Wt Wt R132C Wt Wt Wt G279E Yes – Yes – –
121 M 70 M0 4.3 Yes Wt Wt Wt Wt G12D R420V Wt – – Yes – Yes
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somal lesions represent functionally irrelevant aberrations
and that chromosomal instability is a hallmark of sAML
pathogenesis. The karyotype complexity in sAML is likely
due to longer clonal evolution before leukemic transforma-
tion. A recent study showed that therapies administered
during chronic phase of MPN do not associate with
increased risk of AML transformation, and that 25% of
therapy-naive patients develop AML [40]. However, a dif-
ferent study with longer observation time reported
increased transformation rates in patients treated with
pipobroman or hydroxyurea [41]. It is likely that certain
patient-specific adaptations to therapies might utilize path-
ways promoting leukemic transformation, such as the
DNA damage response pathway. In contrast to sAML,
complex karyotype significantly contributed to poor OS in
the dnAML patients as previously reported [42]. Interest-
ingly, the majority of dnAML patients with complex karyo-
type exhibited genetic features typical for either chronic
phase MPN or sAML. These lesions included mutated
TP53, presence of CUX1 deletions, and deletions of
FOXP1 and ETV6 previously shown to be associated with
chronic MPN [31]. This observation suggests that a num-
ber of patients diagnosed as dnAML with complex karyo-
type might in fact be sAML patients with a previously
undiagnosed MPN or MDS either due to masked chronic
phase phenotypes or absence of hematological examina-
tion preceding leukemic transformation.
We have shown that the genetic features of AML arising
de novo substantially differ from post-MPN and post-MDS
AML. Our data reinforce the fact that dnAML and sAML
should be treated as separate AML subtypes. Furthermore,
genetic resemblance of dnAML with complex karyotype and
sAML indicate that these patients might constitute a rela-
tively homogenous group for therapeutic intervention. This
study demonstrates the use of genetic stratification of AML
patients and suggests that despite the immense genetic
heterogeneity among AML patients, certain markers have
strong influence on patients’ survival.
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